Active Pharmaceutical Ingredient (API) Market Size & Share, by API Type (Branded, Generic); Synthesis Type (Biotech, Synthetic); Application (Cardiology, Oncology, Pulmonology, Neurology, Ophthalmology) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4214
  • Published Date: Feb 20, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Active Pharmaceutical Ingredient Market size is poised to cross USD 475 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of active pharmaceutical ingredient was over USD 236 Billion. The growth of the market can primarily be attributed to the higher prevalence of chronic diseases such as cardiovascular diseases, and cancer across the globe, the rising demand for pharmaceutical drugs, and increasing geopolitical changes. The prevalence of chronic diseases is so high that nearly 40 million people lose their lives annually, out of which, about 15 million of them are classified as premature globally. 

Get more information on this report: Request Free Sample PDF

Active Pharmaceutical Ingredient Sector: Growth Drivers and Challenges

Growth Drivers

  • Escalating Geriatric Population Rising Need for More Formulations - Data provided by the World Bank showed that there were 747,238,580 people aged 65 and above in 2021 around the world. People of elderly age are more likely to get sick or acquire chronic diseases since the body becomes weak with the passing of time. Geriatrics are more dependent on medicines than adults. Hence, this factor is projected to hike the growth of the pharmaceutical ingredient market
  •  over the forecast period.
  • Spiking Cases of Medication Errors that Lead to Increase in Patient Mortality – The U.S. FDA stated in 2019, that it receives over 100,000 reports of medication errors annually. Additionally, over 6 million patients in the United States get affected by some sort of medication error every year.
  • Higher Utilization of APIs to Treat Diabetes Across the World – With the rising indulgence of the population in an unhealthy lifestyle, the prevalence of diabetes among people has grown considerably. Thus, the demand for active pharmaceutical ingredients is expected to increase for the timely treatment of the patient. A report published by the International Diabetes Federation (IDF) estimated the number of people living with diabetes to reach 643 million by 2030 across the world.
  • Spiking Prevalence of Cardiovascular Diseases Owing to Unhealthy Eating Habits and Sedentary Lifestyle – Recently, the cases of cardiovascular diseases have increased drastically owing to an unhealthy diet and reduced physical activity. To treat patients with cardiovascular disease, the need for active pharmaceutical ingredients is expected to grow to create a positive outlook for market growth during the forecast period. Cardiovascular diseases are very prevalent worldwide, for instance, approximately 18 million people die annually due to some sort of cardiovascular disease in the world.
  • Increasing Healthcare Expenditure Per Capita Demanding for API Synthesis – As a result of developing economies, the per capita income of people has also escalated which has ultimately increased the spending capacity in the healthcare sector, and for treatment processes. Hence, the preference for the active pharmaceutical ingredient is anticipated to rise for an effective treatment process. The global healthcare expenditure was projected to rise Y-O-Y reaching about USD 1100 per capita in 2019.


  • Price Policies Changing Periodically - The change in the price policy of drugs impacts the pricing and manufacturing cost of the companies. The unintended price drop can lead to a huge loss for the manufacturers and have a negative impact hindering the growth of the active pharmaceutical ingredient market in the forecast period.
  • Lack of Awareness among the Global Population
  • Higher Price Associated with the Manufacturing Process

Active Pharmaceutical Ingredient Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

USD 236 Billion

Forecast Year Market Size (2035)

USD 475 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Active Pharmaceutical Ingredient Segmentation

Application (Cardiology, Oncology, Pulmonology, Neurology, Ophthalmology)

The global active pharmaceutical ingredient market is segmented and analyzed for demand and supply by application into cardiology, oncology, pulmonology, neurology, ophthalmology, and others. Amongst these segments, cardiology is anticipated to obtain the largest market share during the forecast period. The growth of the segment is ascribed to the higher prevalence of heart diseases, the increasing old population with high blood pressure, growing obesity, and cholesterol issues leading to surgeries or death in severe cases. For instance, approximately 600,000 people die due to heart disease per year solely in the USA.  Furthermore, the surge in the number of cardiac arrest, usage of cardiac implants and heart transplant procedures around the world which require surgical procedures also brings the need for active pharmaceutical ingredients which in turn is anticipated to fuel segment growth.

Synthesis Type (Biotech, Synthetic)

The global active pharmaceutical ingredient market is also segmented and analyzed for demand and supply by biotech and synthetic. Out of these, the synthetic segment is attributed to garnering the highest market share during the forecast period. Owing to the great advantages of synthetic active pharmaceutical ingredients including the low production cost of chemically synthesized ingredients coupled with the reduced cost of raw materials are considered to be major factors anticipated to impetus a significant revenue generation. Furthermore, the easy process of developing these synthetic active pharmaceutical ingredients is considered to be another growth factor for segment expansion in the upcoming years. On the other hand, the biotech segment is also projected to hold a significant market share by growing at a steady CAGR value. The main factor for segment growth is the escalation in the demand for biopharmaceuticals along with the increased number of innovations in biologics to address the unmet medical needs for diseases. Also, the biotech segment attracts big pharmaceutical enterprises and major key players owing to the increased number of FDI approvals for biological drugs and medicines including vaccines, blood components, and recombinant proteins. Hence, all the factors add up to propel segment growth.

Our in-depth analysis of the global active pharmaceutical ingredient market includes the following segments:

       By API Type

  • Branded
  • Generic


       By Synthesis Type

  • Biotech
  • Synthetic


       By Application

  • Cardiology
  • Oncology
  • Pulmonology
  • Neurology
  • Ophthalmology
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Active Pharmaceutical Ingredient Industry - Regional Synopsis

North America Market Forecast

The North American active pharmaceutical ingredient market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035.  The growth of the market in the region can be accounted for by the higher prevalence of cardiovascular diseases. Data provided by the Centers for Disease Control and Prevention stated that every 34 seconds, 1 person dies due to cardiovascular diseases in the USA while in 2020, 697,000 lost their lives due to a similar reason. Furthermore, recent policies of the U.S. government and rising healthcare infrastructure in the region, the rising number of novel drugs, and increasing molecular entities that go off-patent are also anticipated to propel the growth of the market over the forecast period. Furthermore, the presence of a strong healthcare network in the region along with rising healthcare expenditures is also anticipated to boost the market growth.

Asia Pacific Market Forecast

On the other hand, the Asia Pacific active pharmaceutical ingredient market is also projected to hold a significant market share with a noteworthy CAGR over the forecast period. The major factor for market growth is the growing geriatric population coupled with the presence of a large patient pool in the region. In addition, favorable policies by the regulatory bodies that promote the market players to opt for an active pharmaceutical ingredient for timely treatment and supportive reimbursement policies are also expected to contribute to the market growth in the region. In addition, the region's expanding healthcare industry is also expected to boost active pharmaceutical ingredient market growth during the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Active Pharmaceutical Ingredient Landscape

    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Abbott Laboratories
    • AbbVie Inc.
    • Mylan N.V.
    • GSK plc
    • Eli Lilli and Company
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Merck & Co. Inc.


In The News

  • Pfizer Inc. acquires U.S. FDA approval along with Myovant for MYFEMBREE, a once-daily treatment for premenopausal women with endometriosis to reduce non-menstrual and menstrual pain. Additionally, both companies are jointly commercializing MYFEMBREE with immediate product availability.

  • Abbott Laboratories to collaborate with WW International, Inc. to integrate WeightWatchers, a weight management program, to provide requisite assistance to people diagnosed with diabetes and improvise their health issues.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4214
  • Published Date: Feb 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The higher prevalence of chronic diseases across the globe and spiking cases of medication errors are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Higher price associated with the manufacturing process and possibilities of side effects is estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Abbott Laboratories, AbbVie Inc., Mylan N.V., GSK plc, Eli Lilli and Company, Sun Pharmaceutical Industries Ltd., Novartis AG, and Merck & Co. Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by API type, synthesis type, application, by region.

The cardiology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Active Pharmaceutical Ingredient Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying